vTv Therapeutics Inc. - (VTVT) News
Filter VTVT News Items
VTVT News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
VTVT News Highlights
- 500 - Internal server error
- Over the past 14 days, the trend for VTVT's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- The most mentioned tickers in articles about VTVT are RARE.
Latest VTVT News From Around the Web
Below are the latest news stories about vTv Therapeutics Inc that investors may wish to consider to help them evaluate VTVT as an investment opportunity.
Alzheimers Disease Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | Eisai, Biogen, vTv Therapeutics, AZTherapies, Cerecin, EIP Pharma, Neuraly, AB Science and OthersAlzheimers disease is an irreversible, progressive brain disorder that slowly destroys memory and thinking skills and, eventually, the ability to carry out the simplest tasks. In most people with the diseasethose with the late-onset typesymptoms first appear in their mid-60s. Early-onset Alzheimers occurs between a persons 30s and mid-60s and is very rare. Alzheimers disease is [] |
3 Biopharma Penny Stocks That Could be Millionaire MakersThese three biotech penny stocks all have developed drugs that have shown strong indications of success. |
vTv Therapeutics to Participate at the 6th World Psoriasis & Psoriatic Arthritis Conference with Poster Presentation on HPP737HIGH POINT, N.C., June 29, 2021 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT) a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes and psoriasis, today announced that it will be presenting data from the clinical development of HPP737 as a treatment for psoriasis in a poster presentation at the 6th World Psoriasis & Psoriatic Arthritis Conference held virtually June 30 – July 3, 2021 in Stockholm, Sweden. Poster Det |
Tuesday’s Pre-Market: Here’s What You Need to Know Before the Market OpensU.S. stock futures jumped on Tuesday as investors await data of the National Association of Realtors’ existing home sales for May and the non-manufacturing business data of the Federal Reserve Bank of Philadelphia. Both sets of data are scheduled to be released today. Furthermore, the Federal Reserve Bank of Richmond is set to release the results of its monthly survey of manufacturing activity today. S&P, Dow, and Nasdaq futures were in the green at the time of writing, with 0.1%, 0.1%, and 0.3% higher trading, respectively. Cognyte Software (CGNT), Korn Ferry (KFY), and Plug Power (PLUG) are expected to report earnings today. |
vTv Therapeutics Shares Jump On Out-Licensing Agreement For Azeliragon In Cancer SettingsPrivately-held Cantex Pharmaceuticals Inc has entered into a licensing agreement with vTv Therapeutics Inc (NASDAQ: VTVT ) to develop and commercialize vTv''s azeliragon. Under the terms of the agreement, Cantex will be responsible for the development and commercialization of azeliragon, and the companies will allocate downstream profits under Full story available on Benzinga.com |
Where Do Hedge Funds Stand On vTv Therapeutics Inc (VTVT)?No summary available. |
VTv Therapeutics, Cantex Ink Licensing Agreement For Azeliragon To Treat Cancer - Quick Facts(RTTNews) - Biopharmaceutical company vTv Therapeutics Inc. (VTVT) and Cantex Pharmaceuticals, Inc. announced that they have entered into a licensing agreement under which Cantex has obtained exclusive worldwide rights to develop and commercialize azeliragon, vTv''s novel orally active, small molecule, antagonist of RAGE (the receptor for |
vTv Therapeutics and Cantex Pharmaceuticals Announce Strategic Licensing Agreement for Development and Commercialization of Azeliragon for Treatment of CancerHIGH POINT, N.C. and WESTON, Fla., June 22, 2021 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (“vTv”, Nasdaq:VTVT) and Cantex Pharmaceuticals, Inc. (“Cantex”) today announced that they have entered into a licensing agreement under which Cantex has obtained exclusive worldwide rights to develop and commercialize azeliragon, vTv’s novel antagonist of RAGE (the receptor for advanced glycation endproducts). Stephen Marcus, M.D., president and chief executive officer of Cantex, stated: “RAGE has been im |
What Kind Of Shareholders Own vTv Therapeutics Inc. (NASDAQ:VTVT)?The big shareholder groups in vTv Therapeutics Inc. ( NASDAQ:VTVT ) have power over the company. Large companies... |
Analysts think vTv Therapeutics Inc. (NASDAQ:VTVT) could rise 220.51% from current levelsvTv Therapeutics Inc. (NASDAQ:VTVT) price closed higher on Friday, May 14, jumping 3.08% above its previous close. Get the hottest stocks to trade every day before the market opens 100% free. Click here now. A look at the daily price movement shows that the last close reads $2.27, with intraday deals fluctuated between $2.2850 and Analysts think vTv Therapeutics Inc. (NASDAQ:VTVT) could rise 220.51% from current levels Read More » |